Healthcare provider profile · identity verified

Carl R Olden, MD

Family Practice · YAKIMA, WA · NPI 1922022037

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	382	114
Lisinopril	Lisinopril	354	104
Levothyroxine Sodium	Levothyroxine Sodium	269	80
Losartan Potassium	Losartan Potassium	263	75
Metoprolol Succinate	Metoprolol Succinate	221	65
Omeprazole	Omeprazole	214	62
Amlodipine Besylate	Amlodipine Besylate	210	66
Hydrochlorothiazide	Hydrochlorothiazide	171	49
Rosuvastatin Calcium	Rosuvastatin Calcium	163	45
Simvastatin	Simvastatin	147	42
Metformin Hcl Er	Metformin Hcl	143	42
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	137	39
Escitalopram Oxalate	Escitalopram Oxalate	120	30
Gabapentin	Gabapentin	115	33
Trazodone Hcl	Trazodone Hcl	110	34
Pantoprazole Sodium	Pantoprazole Sodium	109	31
Metformin Hcl	Metformin Hcl	104	32
Tamsulosin Hcl	Tamsulosin Hcl	102	31
Glimepiride	Glimepiride	87	23
Albuterol Sulfate Hfa	Albuterol Sulfate	86	25
Potassium Chloride	Potassium Chloride	86	28
Furosemide	Furosemide	82	28
Alprazolam	Alprazolam	76	19
Allopurinol	Allopurinol	72	21
Tramadol Hcl	Tramadol Hcl	72	16
Meloxicam	Meloxicam	68	20
Sertraline Hcl	Sertraline Hcl	68	19
Warfarin Sodium	Warfarin Sodium	67	20
Carvedilol	Carvedilol	64	20
Fluoxetine Hcl	Fluoxetine Hcl	63	16
Pravastatin Sodium	Pravastatin Sodium	63	17
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	59	19
Citalopram Hbr	Citalopram Hydrobromide	56	14
Eliquis	Apixaban	55	17
Lorazepam	Lorazepam	54	15
Metoprolol Tartrate	Metoprolol Tartrate	53	19
Venlafaxine Hcl Er	Venlafaxine Hcl	53	11
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	50	14
Estradiol	Estradiol	43	13
Lovastatin	Lovastatin	43	12
Oxycodone Hcl	Oxycodone Hcl	43	suppressed
Synthroid	Levothyroxine Sodium	40	11
Trulicity	Dulaglutide	40	suppressed
Montelukast Sodium	Montelukast Sodium	39	11
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	38	suppressed
Ropinirole Hcl	Ropinirole Hcl	38	12
Duloxetine Hcl	Duloxetine Hcl	37	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	37	14
Glyxambi	Empagliflozin/Linagliptin	36	11
Methocarbamol	Methocarbamol	36	11
Amitriptyline Hcl	Amitriptyline Hcl	32	11
Bupropion Hcl Sr	Bupropion Hcl	31	suppressed
Fluticasone Propionate	Fluticasone Propionate	31	11
Rybelsus	Semaglutide	31	suppressed
Alendronate Sodium	Alendronate Sodium	30	suppressed
Atenolol	Atenolol	30	suppressed
Ozempic	Semaglutide	29	suppressed
Propranolol Hcl	Propranolol Hcl	29	suppressed
Tizanidine Hcl	Tizanidine Hcl	29	suppressed
Acyclovir	Acyclovir	27	suppressed
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	27	suppressed
Spironolactone	Spironolactone	27	suppressed
Azithromycin	Azithromycin	25	12
Chlorthalidone	Chlorthalidone	25	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	25	17
Ultra-Fine Mini Pen Needle	Pen Needle, Diabetic	25	suppressed
Venlafaxine Hcl	Venlafaxine Hcl	25	suppressed
Buspirone Hcl	Buspirone Hcl	23	suppressed
Paroxetine Hcl	Paroxetine Hcl	23	suppressed
Prednisone	Prednisone	23	12
Valacyclovir	Valacyclovir Hcl	23	suppressed
Cephalexin	Cephalexin	22	suppressed
Fluconazole	Fluconazole	22	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	22	suppressed
Memantine Hcl	Memantine Hcl	22	suppressed
Prazosin Hcl	Prazosin Hcl	22	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	22	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	22	suppressed
Clobetasol Propionate	Clobetasol Propionate	21	suppressed
Clonazepam	Clonazepam	20	suppressed
Clopidogrel	Clopidogrel Bisulfate	20	suppressed
Irbesartan	Irbesartan	20	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	20	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	19	suppressed
Arnuity Ellipta	Fluticasone Furoate	18	suppressed
Bupropion Hcl	Bupropion Hcl	18	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	18	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	18	suppressed
Jardiance	Empagliflozin	17	suppressed
Olanzapine	Olanzapine	17	suppressed
Xarelto	Rivaroxaban	17	suppressed
Bupropion Xl	Bupropion Hcl	16	suppressed
Fiasp Flextouch	Insulin Aspart (Niacinamide)	16	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	16	suppressed
Ondansetron Odt	Ondansetron	16	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	15	suppressed
Glipizide	Glipizide	15	suppressed
Verapamil Er	Verapamil Hcl	15	suppressed
Celecoxib	Celecoxib	14	suppressed
Enalapril Maleate	Enalapril Maleate	14	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	14	suppressed
Ultra-Fine Short Pen Needle	Pen Needle, Diabetic	14	suppressed
Alfuzosin Hcl Er	Alfuzosin Hcl	13	suppressed
Benazepril Hcl	Benazepril Hcl	13	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	13	suppressed
Ezetimibe	Ezetimibe	12	suppressed
Famotidine	Famotidine	12	suppressed
Farxiga	Dapagliflozin Propanediol	12	suppressed
Myrbetriq	Mirabegron	12	suppressed
Naproxen	Naproxen	12	suppressed
Vitamin D2	Ergocalciferol (Vitamin D2)	12	suppressed
Bydureon Bcise	Exenatide Microspheres	11	suppressed
Clonidine	Clonidine	11	suppressed
Donepezil Hcl	Donepezil Hcl	11	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	11	suppressed
Fenofibrate	Fenofibrate	11	suppressed
Glipizide Er	Glipizide	11	suppressed
Pregabalin	Pregabalin	11	suppressed
Rivastigmine	Rivastigmine Tartrate	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error